Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EIF2AK4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EIF2AK4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EIF2AK4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/EIF2AK4_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EIF2AK4_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EIF2AK4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001908018 | Skin | AK | viral gene expression | 21/1910 | 94/18723 | 4.26e-04 | 4.05e-03 | 21 |
GO:00028319 | Skin | AK | regulation of response to biotic stimulus | 53/1910 | 327/18723 | 4.63e-04 | 4.31e-03 | 53 |
GO:00447889 | Skin | AK | modulation by host of viral process | 10/1910 | 30/18723 | 5.26e-04 | 4.79e-03 | 10 |
GO:003166924 | Skin | AK | cellular response to nutrient levels | 38/1910 | 215/18723 | 5.37e-04 | 4.86e-03 | 38 |
GO:001908117 | Skin | AK | viral translation | 7/1910 | 16/18723 | 5.66e-04 | 5.06e-03 | 7 |
GO:00346446 | Skin | AK | cellular response to UV | 20/1910 | 90/18723 | 6.22e-04 | 5.45e-03 | 20 |
GO:19019884 | Skin | AK | negative regulation of cell cycle phase transition | 42/1910 | 249/18723 | 7.65e-04 | 6.39e-03 | 42 |
GO:00510909 | Skin | AK | regulation of DNA-binding transcription factor activity | 66/1910 | 440/18723 | 8.99e-04 | 7.40e-03 | 66 |
GO:00094116 | Skin | AK | response to UV | 28/1910 | 149/18723 | 1.05e-03 | 8.24e-03 | 28 |
GO:005170215 | Skin | AK | biological process involved in interaction with symbiont | 20/1910 | 94/18723 | 1.11e-03 | 8.63e-03 | 20 |
GO:00448276 | Skin | AK | modulation by host of viral genome replication | 7/1910 | 19/18723 | 1.89e-03 | 1.29e-02 | 7 |
GO:000926720 | Skin | AK | cellular response to starvation | 28/1910 | 156/18723 | 2.15e-03 | 1.43e-02 | 28 |
GO:00000776 | Skin | AK | DNA damage checkpoint | 22/1910 | 115/18723 | 2.74e-03 | 1.74e-02 | 22 |
GO:00109485 | Skin | AK | negative regulation of cell cycle process | 45/1910 | 294/18723 | 3.73e-03 | 2.22e-02 | 45 |
GO:00094166 | Skin | AK | response to light stimulus | 48/1910 | 320/18723 | 4.20e-03 | 2.45e-02 | 48 |
GO:004259420 | Skin | AK | response to starvation | 32/1910 | 197/18723 | 5.47e-03 | 3.02e-02 | 32 |
GO:00315706 | Skin | AK | DNA integrity checkpoint | 22/1910 | 123/18723 | 6.33e-03 | 3.38e-02 | 22 |
GO:00714822 | Skin | AK | cellular response to light stimulus | 22/1910 | 123/18723 | 6.33e-03 | 3.38e-02 | 22 |
GO:00000755 | Skin | AK | cell cycle checkpoint | 28/1910 | 169/18723 | 6.83e-03 | 3.60e-02 | 28 |
GO:00435586 | Skin | AK | regulation of translational initiation in response to stress | 5/1910 | 14/18723 | 1.00e-02 | 4.80e-02 | 5 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EIF2AK4 | SNV | Missense_Mutation | novel | c.1790N>T | p.Gly597Val | p.G597V | Q9P2K8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A4RX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EIF2AK4 | SNV | Missense_Mutation | novel | c.236N>A | p.Cys79Tyr | p.C79Y | Q9P2K8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A7-A6VV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
EIF2AK4 | SNV | Missense_Mutation | | c.3685G>A | p.Asp1229Asn | p.D1229N | Q9P2K8 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
EIF2AK4 | SNV | Missense_Mutation | | c.3796G>A | p.Asp1266Asn | p.D1266N | Q9P2K8 | protein_coding | tolerated(0.96) | benign(0.01) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
EIF2AK4 | SNV | Missense_Mutation | | c.1724N>C | p.Phe575Ser | p.F575S | Q9P2K8 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-AO-A1KR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
EIF2AK4 | SNV | Missense_Mutation | rs763402151 | c.1378N>C | p.Glu460Gln | p.E460Q | Q9P2K8 | protein_coding | tolerated(0.09) | probably_damaging(0.999) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EIF2AK4 | SNV | Missense_Mutation | | c.4701N>C | p.Gln1567His | p.Q1567H | Q9P2K8 | protein_coding | tolerated(0.76) | benign(0.007) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
EIF2AK4 | SNV | Missense_Mutation | rs752767858 | c.2345N>C | p.Gly782Ala | p.G782A | Q9P2K8 | protein_coding | tolerated(0.67) | benign(0.019) | TCGA-C8-A12X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EIF2AK4 | SNV | Missense_Mutation | novel | c.301G>A | p.Glu101Lys | p.E101K | Q9P2K8 | protein_coding | deleterious(0.01) | possibly_damaging(0.808) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EIF2AK4 | SNV | Missense_Mutation | | c.3791A>C | p.Lys1264Thr | p.K1264T | Q9P2K8 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-D8-A1JL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
440275 | EIF2AK4 | KINASE, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | | olanzapine | OLANZAPINE | 24751813 |
440275 | EIF2AK4 | KINASE, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | | risperidone | RISPERIDONE | 24751813 |
440275 | EIF2AK4 | KINASE, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 249565849 | | |
440275 | EIF2AK4 | KINASE, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | | quetiapine | QUETIAPINE | 24751813 |
440275 | EIF2AK4 | KINASE, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
440275 | EIF2AK4 | KINASE, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | | haloperidol | HALOPERIDOL | 27023437,24751813 |
440275 | EIF2AK4 | KINASE, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | | ziprasidone | ZIPRASIDONE | 24751813 |